Voleon Capital Management LP lowered its stake in Colgate-Palmolive (NYSE:CL) by 8.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 110,000 shares of the company’s stock after selling 10,000 shares during the period. Voleon Capital Management LP’s holdings in Colgate-Palmolive were worth $7,884,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in CL. Nuveen Asset Management LLC increased its holdings in Colgate-Palmolive by 16,117.1% during the 2nd quarter. Nuveen Asset Management LLC now owns 6,435,107 shares of the company’s stock valued at $461,204,000 after purchasing an additional 6,395,426 shares during the period. Invesco Ltd. increased its holdings in Colgate-Palmolive by 201.8% during the 2nd quarter. Invesco Ltd. now owns 8,642,044 shares of the company’s stock valued at $619,374,000 after purchasing an additional 5,778,145 shares during the period. FMR LLC increased its holdings in Colgate-Palmolive by 29.1% during the 1st quarter. FMR LLC now owns 7,384,604 shares of the company’s stock valued at $506,141,000 after purchasing an additional 1,665,348 shares during the period. AQR Capital Management LLC increased its holdings in Colgate-Palmolive by 52.2% during the 2nd quarter. AQR Capital Management LLC now owns 3,485,442 shares of the company’s stock valued at $249,801,000 after purchasing an additional 1,195,074 shares during the period. Finally, Vanguard Group Inc. increased its holdings in Colgate-Palmolive by 1.4% during the 2nd quarter. Vanguard Group Inc. now owns 76,502,840 shares of the company’s stock valued at $5,482,958,000 after purchasing an additional 1,056,530 shares during the period. Hedge funds and other institutional investors own 75.95% of the company’s stock.
Colgate-Palmolive stock traded up $0.99 during trading hours on Tuesday, hitting $72.49. 4,272,477 shares of the stock traded hands, compared to its average volume of 3,022,701. The firm’s 50-day moving average price is $72.20 and its two-hundred day moving average price is $71.09. The company has a current ratio of 1.13, a quick ratio of 0.78 and a debt-to-equity ratio of 32.25. The company has a market cap of $60.88 billion, a PE ratio of 24.41, a PEG ratio of 4.57 and a beta of 0.75. Colgate-Palmolive has a one year low of $57.41 and a one year high of $76.41.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 15th. Shareholders of record on Wednesday, October 23rd will be given a dividend of $0.43 per share. The ex-dividend date is Tuesday, October 22nd. This represents a $1.72 annualized dividend and a yield of 2.37%. Colgate-Palmolive’s payout ratio is 57.91%.
In other Colgate-Palmolive news, CFO Henning I. Jakobsen sold 33,854 shares of Colgate-Palmolive stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $73.45, for a total transaction of $2,486,576.30. Following the sale, the chief financial officer now directly owns 73,693 shares of the company’s stock, valued at approximately $5,412,750.85. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Ian M. Cook sold 175,616 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $72.65, for a total value of $12,758,502.40. Following the completion of the sale, the insider now directly owns 1,125,842 shares in the company, valued at $81,792,421.30. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 569,298 shares of company stock worth $40,914,565. Insiders own 1.14% of the company’s stock.
A number of research analysts recently issued reports on CL shares. Zacks Investment Research downgraded Colgate-Palmolive from a “buy” rating to a “hold” rating and set a $77.00 price target on the stock. in a report on Friday, June 7th. Wells Fargo & Co boosted their price target on Colgate-Palmolive from $68.00 to $70.00 and gave the company a “market perform” rating in a report on Monday, July 29th. Morgan Stanley boosted their price target on Colgate-Palmolive from $72.00 to $74.00 and gave the company an “equal weight” rating in a report on Monday, July 29th. Bank of America set a $80.00 price target on Colgate-Palmolive and gave the company a “buy” rating in a report on Friday, July 12th. Finally, UBS Group boosted their price target on Colgate-Palmolive from $80.00 to $82.00 and gave the company a “buy” rating in a report on Monday, July 29th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and six have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $74.07.
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. It offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; and personal care products, such as liquid hand soaps, bar soaps, shower gels, deodorants and antiperspirants, skin care products, and shampoos and conditioners.
Featured Article: Balanced Fund
Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.